Staphylococcal Skin and Soft Tissue Infections.
Abscess
/ microbiology
Algorithms
Anti-Bacterial Agents
/ therapeutic use
Cellulitis
/ microbiology
Drainage
/ methods
Humans
Impetigo
/ microbiology
Methicillin Resistance
Methicillin-Resistant Staphylococcus aureus
/ pathogenicity
Risk Factors
Soft Tissue Infections
/ diagnosis
Staphylococcal Skin Infections
/ diagnosis
Staphylococcus aureus
/ pathogenicity
Acute bacterial skin and skin structure infections
Cellulitis with abscess
Purulent cellulitis
Staphylococcus aureus skin infection
Suppurative cellulitis
Journal
Infectious disease clinics of North America
ISSN: 1557-9824
Titre abrégé: Infect Dis Clin North Am
Pays: United States
ID NLM: 8804508
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
pubmed:
12
12
2020
medline:
30
10
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
Staphylococcus aureus is the most common bacteria causing purulent skin and soft tissue infections. Many disease-causing S aureus strains are methicillin resistant; thus, empiric therapy should be given to cover methicillin-resistant S aureus. Bacterial wound cultures are important for characterizing local susceptibility patterns. Definitive antibiotic therapy is warranted, although there are no compelling data demonstrating superiority of any one antibiotic over another. Antibiotic choice is predicated by the infection severity, local susceptibility patterns, and drug-related safety, tolerability, and cost. Response to therapy is expected within the first days; 5 to 7 days of therapy is typically adequate to achieve cure.
Identifiants
pubmed: 33303329
pii: S0891-5520(20)30082-9
doi: 10.1016/j.idc.2020.10.003
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
81-105Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure Dr L.G. Miller has received grants from Merck. Dr T.J. Hatlen has nothing to disclose.